Hyung-Sik Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hyung-Sik Lee has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Hyuk-Chan Kwon
Department of Hemato-oncology, Dong-A University School of Medicine, Busan, Korea
2 shared publications- Jee Suk Chang
Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea
2 shared publications - Jin Ho Kim
Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea
2 shared publications - Jong Hoon Lee
Department of Radiation Oncology, College of Medicine, St. Vincent`s Hospital, The Catholic University of Korea, Suwon, Republic of Korea
2 shared publications - Sung-Ja Ahn
Department of Radiation Oncology, Lung and Esophageal Cancer Clinic, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Republic of Korea
2 shared publications - Won Park
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2 shared publications
Latest Publications
- Open Access
Comparison of Dose Distribution in Regional Lymph Nodes in Whole-Breast Radiotherapy vs. Whole-Breast Plus Regional Lymph Node Irradiation: An In Silico Planning Study in Participating Institutions of the Phase III Randomized Trial (KROG 1701)
The purpose of the current in silico planning study is to compare radiation doses of whole-breast irradiation (WBI) and whole-breast plus regional lymph node irradiation (WBI+RNI) administered to the regional lymph nodes (RLN) in pN1 breast cancer. Twenty-four participating institutions were asked to create plans of WBI and WBI+RNI for two dummy cases. To compare target coverage between the participants, an isodose line equal to 90% of the prescribed dose was converted to an isodose contour (contour90% iso). The relative nodal dose (RND) was obtained using the ratio of RLN dose to the target dose. The Fleiss’s kappa values which represent inter-observer agreement of contour90% iso were over 0.68. For RNI, 6 institutions included axillary lymph node (ALN), supraclavicular lymph node (SCN), and internal mammary lymph node (IMN), while 18 hospitals included only ALN and SCN. The median RND between the WBI and WBI+RNI were as follows: 0.64 vs. 1.05 (ALN level I), 0.27 vs. 1.08 (ALN level II), 0.02 vs. 1.12 (ALN level III), 0.01 vs. 1.12 (SCN), and 0.54 vs. 0.82 (IMN). In all nodal regions, the RND was significantly lower in WBI than in WBI+RNI (p < 0.01). In this study, we could identify the nodal dose difference between WBI and WBI+RNI.
Open AccessComparison of Dose Distribution in Regional Lymph Nodes in Whole-Breast Radiotherapy vs. Whole-Breast Plus Regional Lymph Node Irradiation: An In Silico Planning Study in Participating Institutions of the Phase III Randomized Trial (KROG 1701)
The purpose of the current in silico planning study is to compare radiation doses of whole-breast irradiation (WBI) and whole-breast plus regional lymph node irradiation (WBI+RNI) administered to the regional lymph nodes (RLN) in pN1 breast cancer. Twenty-four participating institutions were asked to create plans of WBI and WBI+RNI for two dummy cases. To compare target coverage between the participants, an isodose line equal to 90% of the prescribed dose was converted to an isodose contour (contour90% iso). The relative nodal dose (RND) was obtained using the ratio of RLN dose to the target dose. The Fleiss’s kappa values which represent inter-observer agreement of contour90% iso were over 0.68. For RNI, 6 institutions included axillary lymph node (ALN), supraclavicular lymph node (SCN), and internal mammary lymph node (IMN), while 18 hospitals included only ALN and SCN. The median RND between the WBI and WBI+RNI were as follows: 0.64 vs. 1.05 (ALN level I), 0.27 vs. 1.08 (ALN level II), 0.02 vs. 1.12 (ALN level III), 0.01 vs. 1.12 (SCN), and 0.54 vs. 0.82 (IMN). In all nodal regions, the RND was significantly lower in WBI than in WBI+RNI (p < 0.01). In this study, we could identify the nodal dose difference between WBI and WBI+RNI.
- Open Access
Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study
This study evaluated the clinical significance of the lymph-node ratio (LNR) and its usefulness as an indicator of supraclavicular lymph-node radiation therapy (SCNRT) in pN1 breast cancer patients with disease-free survival (DFS) outcomes. We retrospectively analyzed the clinical data of patients with pN1 breast cancer who underwent partial mastectomy and taxane-based sequential adjuvant chemotherapy with postoperative radiation therapy in 12 hospitals (n = 1121). We compared their DFS according to LNR, with a cut-off value of 0.10. The median follow-up period was 66 months (range, 3–112). Treatment failed in 73 patients (6.5%) and there was no significant difference in DFS between the SCNRT group and non-SCNRT group. High LNR (>0.10) showed significantly worse DFS in both univariate and multivariate analyses (0.010 and 0.033, respectively). In a subgroup analysis, the effect of SCNRT on DFS differed significantly among patients with LNR > 0.10 (p = 0.013). High LNR can be used as an independent prognostic factor for pN1 breast cancer patients treated with partial mastectomy and postoperative radiotherapy. It may also be useful in deciding whether to perform SCNRT to improve DFS.
Open AccessClinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study
This study evaluated the clinical significance of the lymph-node ratio (LNR) and its usefulness as an indicator of supraclavicular lymph-node radiation therapy (SCNRT) in pN1 breast cancer patients with disease-free survival (DFS) outcomes. We retrospectively analyzed the clinical data of patients with pN1 breast cancer who underwent partial mastectomy and taxane-based sequential adjuvant chemotherapy with postoperative radiation therapy in 12 hospitals (n = 1121). We compared their DFS according to LNR, with a cut-off value of 0.10. The median follow-up period was 66 months (range, 3–112). Treatment failed in 73 patients (6.5%) and there was no significant difference in DFS between the SCNRT group and non-SCNRT group. High LNR (>0.10) showed significantly worse DFS in both univariate and multivariate analyses (0.010 and 0.033, respectively). In a subgroup analysis, the effect of SCNRT on DFS differed significantly among patients with LNR > 0.10 (p = 0.013). High LNR can be used as an independent prognostic factor for pN1 breast cancer patients treated with partial mastectomy and postoperative radiotherapy. It may also be useful in deciding whether to perform SCNRT to improve DFS.
- Open Access
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (36) , 12900-12907
Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection?
Studies from the Far East have demonstrated that D2-dissection is superior to D0/1-dissection. The effect of postoperative chemoradiotherapy (CRT) after D2-dissection has not been accepted due to the lack of D2-dissection in Western countries, as well as the potential harmful effect of radiotherapy. In the current NCCN guideline, adjuvant chemotherapy alone is recommended in D2-dissected patients. However, three recent prospective randomized controlled trials in South Korea and China (ARTIST, NCC and Multicenter IMRT Trials) demonstrated that adjuvant CRT can be safely administered to D2-dissected patients with notable benefits. To identify the role of radiotherapy (RT) in the D2-dissected postoperative setting, clinical research attempts should include (1) identification of high-risk patients for loco-regional recurrence who might benefit from CRT; (2) modification of RT target volume based on the findings that failure patterns should be different after D1- and D2-dissection; and (3) integration of new RT techniques to decrease treatment-related toxicity. The present paper is a review of recent studies addressing these fields. Well-designed prospective randomized studies are needed to clearly define the role of adjuvant CRT in D2-dissected gastric cancer, however, future clinical studies should also focus on answering these questions.
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (36) , 12900-12907
Open AccessPostoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection?
Studies from the Far East have demonstrated that D2-dissection is superior to D0/1-dissection. The effect of postoperative chemoradiotherapy (CRT) after D2-dissection has not been accepted due to the lack of D2-dissection in Western countries, as well as the potential harmful effect of radiotherapy. In the current NCCN guideline, adjuvant chemotherapy alone is recommended in D2-dissected patients. However, three recent prospective randomized controlled trials in South Korea and China (ARTIST, NCC and Multicenter IMRT Trials) demonstrated that adjuvant CRT can be safely administered to D2-dissected patients with notable benefits. To identify the role of radiotherapy (RT) in the D2-dissected postoperative setting, clinical research attempts should include (1) identification of high-risk patients for loco-regional recurrence who might benefit from CRT; (2) modification of RT target volume based on the findings that failure patterns should be different after D1- and D2-dissection; and (3) integration of new RT techniques to decrease treatment-related toxicity. The present paper is a review of recent studies addressing these fields. Well-designed prospective randomized studies are needed to clearly define the role of adjuvant CRT in D2-dissected gastric cancer, however, future clinical studies should also focus on answering these questions.
- Open Access
- 1 January 2013
- Published by Korean Society for Therapeutic Radiology and Oncology in Radiation Oncology Journal
- Vol. 31 (2) , 57-65
Enhancement of radiation effect using beta-lapachone and underlying mechanism
Ahn KJ, et al. Radiat Oncol J. 2013 Jun;31(2):57-65. http://dx.doi.org/10.3857/roj.2013.31.2.57
- 1 January 2013
- Published by Korean Society for Therapeutic Radiology and Oncology in Radiation Oncology Journal
- Vol. 31 (2) , 57-65
Open AccessEnhancement of radiation effect using beta-lapachone and underlying mechanism
Ahn KJ, et al. Radiat Oncol J. 2013 Jun;31(2):57-65. http://dx.doi.org/10.3857/roj.2013.31.2.57
- Open Access
- 31 March 2009
- Published by The Korean Society for Medical Ethics in Korean Journal of Medical Ethics
- Vol. 12 (1) , 1-14
The Process of Medical Decision-making for Cancer Patients
Purpose: This study was performed to evaluate the perception and attitudes of cancer patients regarding medical decision-making. Method: A clinical survey was conducted using questionnaires consisting of 8 items for cancer patients and 11 items for dependents. Both patients and dependents were interviewed. Two hundred and ninety-four people (147 pairs) participated in this survey. The results of the survey were evaluated to see how attitudes concerning medical decision-making differ. Results: The majority of both patients and dependents (more than 90% for each group) gave positive answers to the question of whether the doctor explained the patient’s condition. Also, the majority of both patients and dependents (approximately 90%) were informed about treatment options. Fifty eight percent of the patients and 73% of dependents think that the family is entitled to be informed about the course of treatment and treatment options. In response to the question of which person should decide the course of treatment in the case of disagreement, about 47% of patients and dependents think that the patient should decide, but 14% and 22%, respectively, think that the family should. When making decisions regarding treatment, both patients and dependents consider that improvement in health is the main consideration, followed by the alleviation or avoidance of pain. The lack of information and the pain of the patient are the source of most difficulties. Conclusion: The survey results show that the majority of both cancer patients and their family members think that family members are entitled to be informed of treatment options and have a right to make decisions regarding treatment. The survey also indicates that the majority of patients and family members believe that patients themselves should make treatment decisions in the event of disagreements between patients and family members.
- 31 March 2009
- Published by The Korean Society for Medical Ethics in Korean Journal of Medical Ethics
- Vol. 12 (1) , 1-14
Open AccessThe Process of Medical Decision-making for Cancer Patients
Purpose: This study was performed to evaluate the perception and attitudes of cancer patients regarding medical decision-making. Method: A clinical survey was conducted using questionnaires consisting of 8 items for cancer patients and 11 items for dependents. Both patients and dependents were interviewed. Two hundred and ninety-four people (147 pairs) participated in this survey. The results of the survey were evaluated to see how attitudes concerning medical decision-making differ. Results: The majority of both patients and dependents (more than 90% for each group) gave positive answers to the question of whether the doctor explained the patient’s condition. Also, the majority of both patients and dependents (approximately 90%) were informed about treatment options. Fifty eight percent of the patients and 73% of dependents think that the family is entitled to be informed about the course of treatment and treatment options. In response to the question of which person should decide the course of treatment in the case of disagreement, about 47% of patients and dependents think that the patient should decide, but 14% and 22%, respectively, think that the family should. When making decisions regarding treatment, both patients and dependents consider that improvement in health is the main consideration, followed by the alleviation or avoidance of pain. The lack of information and the pain of the patient are the source of most difficulties. Conclusion: The survey results show that the majority of both cancer patients and their family members think that family members are entitled to be informed of treatment options and have a right to make decisions regarding treatment. The survey also indicates that the majority of patients and family members believe that patients themselves should make treatment decisions in the event of disagreements between patients and family members.
- Open Access
- 1 January 2008
- Published by Korean Society for Therapeutic Radiology and Oncology in The Journal of the Korean Society for Therapeutic Radiology and Oncology
- Vol. 26 (2) , 104-112
A Phase I/II Trial of DCVac/IR® Dendritic Cell Immunotherapy Combined with Irradiation in Cases of Refractory Colorectal Cancer with Multiple Liver Metastases
- 1 January 2008
- Published by Korean Society for Therapeutic Radiology and Oncology in The Journal of the Korean Society for Therapeutic Radiology and Oncology
- Vol. 26 (2) , 104-112
Open AccessA Phase I/II Trial of DCVac/IR® Dendritic Cell Immunotherapy Combined with Irradiation in Cases of Refractory Colorectal Cancer with Multiple Liver Metastases
- Open Access
- 1 January 2006
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 12 (4) , 603-607
Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: Adjuvant 5-FU/cisplatin and chemoradiation with capecitabine
AIM: To evaluate the efficacy and toxicity of postoperative chemoradiation using FP chemotherapy and oral capecitabine during radiation for advanced gastric cancer following curative resection. METHODS: Thirty-one patients who had underwent a potentially curative resection for Stage III and IV (M0) gastric cancer were enrolled. Therapy consists of one cycle of FP (continuous infusion of 5-FU 1000 mg/m2 on d 1 to 5 and cisplatin 60 mg/m2 on d 1) followed by 4500 cGy (180 cGy/d) with capecitabine (1650 mg/m2 daily throughout radiotherapy). Four wk after completion of the radiotherapy, patients received three additional cycles of FP every three wk. The median follow-up duration was 22.2 mo. RESULTS: The 3-year disease free and overall survival in this study were 82.7% and 83.4%, respectively. Four patients (12.9%) showed relapse during follow-up. Eight patients did not complete all planned adjuvant therapy. Grade 3/4 toxicities included neutropenia in 50.2%, anemia in 12.9%, thrombocytopenia in 3.2% and nausea/vomiting in 3.2%. Neither grade 3/4 hand foot syndrome nor treatment related febrile neutropenia or death were observed. CONCLUSION: These preliminary results suggest that this postoperative adjuvant chemoradiation regimen of FP before and after capecitabine and concurrent radiotherapy appears well tolerated and offers a comparable toxicity profile to the chemoradiation regimen utilized in INT-0116. This treatment modality allowed successful loco-regional control rate and 3-year overall survival.
- 1 January 2006
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 12 (4) , 603-607
Open AccessPilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: Adjuvant 5-FU/cisplatin and chemoradiation with capecitabine
AIM: To evaluate the efficacy and toxicity of postoperative chemoradiation using FP chemotherapy and oral capecitabine during radiation for advanced gastric cancer following curative resection. METHODS: Thirty-one patients who had underwent a potentially curative resection for Stage III and IV (M0) gastric cancer were enrolled. Therapy consists of one cycle of FP (continuous infusion of 5-FU 1000 mg/m2 on d 1 to 5 and cisplatin 60 mg/m2 on d 1) followed by 4500 cGy (180 cGy/d) with capecitabine (1650 mg/m2 daily throughout radiotherapy). Four wk after completion of the radiotherapy, patients received three additional cycles of FP every three wk. The median follow-up duration was 22.2 mo. RESULTS: The 3-year disease free and overall survival in this study were 82.7% and 83.4%, respectively. Four patients (12.9%) showed relapse during follow-up. Eight patients did not complete all planned adjuvant therapy. Grade 3/4 toxicities included neutropenia in 50.2%, anemia in 12.9%, thrombocytopenia in 3.2% and nausea/vomiting in 3.2%. Neither grade 3/4 hand foot syndrome nor treatment related febrile neutropenia or death were observed. CONCLUSION: These preliminary results suggest that this postoperative adjuvant chemoradiation regimen of FP before and after capecitabine and concurrent radiotherapy appears well tolerated and offers a comparable toxicity profile to the chemoradiation regimen utilized in INT-0116. This treatment modality allowed successful loco-regional control rate and 3-year overall survival.